Carboplatin and Renal Dysfunction
Authors: Eddie Reed
Journal: Annals of Internal Medicine (1989)

Letters and Corrections1 March 1989Carboplatin and Renal DysfunctionEddie Reed, MD, Joan Jacob, RN, MSNEddie Reed, MDSearch for more papers by this author, Joan Jacob, RN, MSNSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-5-409_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:Carboplatin is a second-generation platinum analogue that has activity in refractory ovarian cancer similar to that of cisplatin (1). Carboplatin appears to have a spectrum of clinical toxicity different from that of cisplatin: at therapeutically equivalent doses, the dose-limiting toxicity for carboplatin is myelosuppression, with comparatively little renal or neurologic toxicity (1-3). For this reason, we have begun to study the use of high-dose carboplatin therapy (800 mg/m2body surface area · cycle) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with refractory ovarian cancer. It is anticipated that GM-CSF may blunt carboplatin-induced bone marrow suppression,...References1. ReedPoirierYoungOzols EMRR. High dose cisplatin in hypertonic saline: toxicity versus therapeutic benefit. In: Hacker MP, Lazo JS, Tritton TR, eds. Organ Directed Toxicities of Anti-Cancer Drugs. Boston: Martinus Nijhoff Publishers; 1988:203-13. CrossrefGoogle Scholar2. OzolsCordenJacobWesleyOstchegaYoung RBJMYR. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100:19-24. LinkGoogle Scholar3. OzolsOstchegaCurtYoung RYGR. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol. 1987;5:197-201. CrossrefMedlineGoogle Scholar4. AntmanGriffinElias KJA. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988;319:593-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: National Cancer Institute National Institutes of Health Bethesda, MD 20892 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byConventional chemotherapyPreparing the Patient for HSCT: Conditioning Regimens and Their Scientific RationaleImpact des traitements utilisés en oncologie thoracique sur la fonction rénaleNickel, Ruthenium, Rhodium, Palladium, Osmium, and PlatinumNephrotoxicity of cancer treatment in childrenAnticancer drugsRenal Pelvic Hemorrhage and Acute Renal Failure Associated with Carboplatin TherapyMaternal–fetal transport kinetics of carboplatin in the perfused human placental lobule: In vitro studyToxicité rénale des anticancéreuxToxicité rénale des anticancéreuxAnticancer drugsNickel, Ruthenium, Rhodium, Palladium, Osmium, and PlatinumRenal and Metabolic Complications of CancerNew Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid TumorsAnticancer: Cisplatin/carboplatinChemotherapy for Patients with Recurrent or Refractory Neuroblastoma: A POG Phase II StudyProgrammed Instruction: Cancer TherapyLong-Term Complications of Antineoplastic AgentsCytostatics and immuno-suppressive drugsNephrotoxicity of cisplatin, carboplatin and transplatinCarboplatin and Renal FunctionEgbert F. Smit, MD, Dirk Th. Sleijfer, MD, Sijtze Meijer, MD, Nanno H. Mulder, Pieter E. Postmus, MD 1 March 1989Volume 110, Issue 5Page: 409-409KeywordsBody surface areaBone marrowGranulocyte macrophage colony stimulating factorOvarian cancerRenal cancerToxicity Issue Published: 1 March 1989 PDF downloadLoading ...